Neuroblastoma Conference Videos 2007

CNCF 2007 Conference Introduction

2008-03-06T18:41:00Z

Pat Tallungan, President of the Children's Neuroblastoma Cancer Foundation, presents the introduction to the 2007 Children's Neuroblastoma Cancer Foundation's Neuroblastoma Conference June 29, 2007 in Chicago, Il.

Overview of Neuroblastoma

2008-03-06T18:33:00Z

Susan L. Cohn, M.D., Director of Clinical Research, Pediatric Hematology/Oncology at the University of Chicago presents an overview of neuroblastoma. This presentation was made at the Children's Neuroblastoma Cancer Foundation's Neuroblastoma Conference on June 29, 2007.

Drug Development for Children with Cancer

2008-03-06T18:23:00Z

Dr. Peter Adamson, Chief, Division of Clinical Pharmacology and Therapeutics
Director, Experimental Therapeutics in Oncology, The Children’s Hospital of Philadelphia provides an overview of the clinical trial process. This presentation was made at the Children's Neuroblastoma Cancer Foundation's Neuroblastoma Conference on June 29, 2007.

Neuroblastoma - Molecular Pathways to Cure

2008-03-06T18:21:00Z

Dr. Kate Matthay, Division Chief, Pediatric Hematology/Oncology, UCSF and Leader, NANT Consortium presents current NANT protocols, study rationale, and information regarding the NANT and phase 1 trials. This presentation was made at the Children's Neuroblastoma Cancer Foundation's Neuroblastoma Conference on June 29, 2007.

Late effects of neuroblastoma and its treatments

2008-03-06T18:17:00Z

James G. Gurney, Ph.D. University of Minnesota, provided an overview of his long-term survivor study issues for children with neuroblastoma. This presentation was made at the Children's Neuroblastoma Cancer Foundation's Neuroblastoma Conference on June 29, 2007 before his COG article on this subject was published. The reference to the published article is "Hearing Loss, Quality of Life, and Academic Problems in Long-term Neuroblastoma Survivors: A Report From the Children's Oncology Group.", PEDIATRICS Vol. 120 No. 5 November 2007, pp. e1229-e1236 (doi:10.1542/peds.2007-0178)

Neuropsychological Late Effects of Neuroblastoma Treatment

2008-03-06T18:15:00Z

Stephen A. Sands, Psy.D. is an Assistant Professor in Pediatrics and Psychiatry at the Columbia University Medical Center. He also serves as the Director of the Valerie Fund Psycho-Social Program at the Herbert Irving Child and Adolescent Oncology Center. During this discussion he provides a historical review of the literature relating to the neurophsycological late effects from treatment of neuroblastoma. This presentation was made at the Children's Neuroblastoma Cancer Foundation's Neuroblastoma Conference on June 29, 2007.

A Look at What Data Should Guide the Study of New Drugs in Neuroblastoma

2008-03-06T18:10:00Z

Dr. Patrick Reynolds, MD PhD, Director, Developmental Therapeutics Program,
USC / CHLA Institute for Pediatric Clinical Research provides an overview of the neuroblastoma research process to help the public understand research data and how it should be interpreted. This presentation was made at the Children's Neuroblastoma Cancer Foundation's Neuroblastoma Conference on June 30, 2007.

Zoledronic Acid (Zometa) in Neuroblastoma

2008-03-06T18:05:00Z

Heidi V. Russell, M.D. Assistant Professor, Department of Pediatrics, Section of Hematology-Oncology, Baylor College of Medicine and study chair of the NANT trial “A Phase I Study of Zoledronic Acid (Zometa) with Cyclophosphamide in Children with Recurrent/Refractory Neuroblastoma and Cortical Bone Involvement.” In this presentation she discusses bone metastases and Zoledronic Acid. This presentation was made at the Children's Neuroblastoma Cancer Foundation's Neuroblastoma Conference on June 29, 2007.

Nifurtimox as a novel therapy for Neuroblastoma

2008-03-06T18:01:00Z

Giselle Sholler, M.D., Assistant Professor of Pediatrics, Vermont Cancer Center, University of Vermont, presents her preclinical and clinical data regarding Nifurtimox and its potential use in the treatment of neuroblastoma. This presentation was made at the Children's Neuroblastoma Cancer Foundation's Neuroblastoma Conference on June 30, 2007.

OMS and Neuroblastoma

2008-03-06T17:54:00Z

Wendy Mitchell M.D., Neurology Division, Childrens Hospital Los Angeles discusses Opsoclonus-Ataxia Syndrome and its relationship to neuroblastoma. This presentation was made at the Children's Neuroblastoma Cancer Foundation's Neuroblastoma Conference on June 30, 2007.

Intermediate Risk Neuroblastoma

2008-03-06T17:51:00Z

Clare Twist, M.D., Associate Professor, Department of Pediatrics – Hematology / Oncology, Stanford School of Medicine. She is the Study Chair for the current COG Phase III Study for the treatment of children with Intermediate Risk Neuroblastoma. I am also the Principal Investigator at Stanford for the New Advances in Neuroblastoma (NANT) Consortium. IN this video she discusses intermediate risk neuroblastoma and its treatment. This presentation was made at the Children's Neuroblastoma Cancer Foundation's Neuroblastoma Conference on June 30, 2007.

Current Therapy for High-Risk Neuroblastoma and COG Stem Cell Transplant Plans

2008-03-06T17:47:00Z

Stephan A. Grupp, MD, PhD, Attending physician; Medical Director, Stem Cell Laboratory, Children’s Hospital of Philadelphia presents the upcoming COG phase III transplant study and discusses various transplant related research. This presentation was made at the Children's Neuroblastoma Cancer Foundation's Neuroblastoma Conference on June 30, 2007.

Erik Ludwinski - My Journey

2008-03-06T07:19:00Z

Erik Ludwinski shares his story about his journey through the world of neuroblastoma.

Molly Hollway - Neuroblastoma Survivor

2008-03-06T07:14:00Z

Molly Hollway, Neuroblastoma Stage III Cancer Survivor

Lunch for Life and Conference Closing Remarks

2008-03-06T07:03:00Z

Mark Dungan provides an overview of Lunch for Life and other programs for the CNCF. Pat Tallungan thanks all of the oncologists and families for their participation.